Karo Begins Phase IIb Study With Dyslipidemia Candidate

Swedish drug company Karo Bio has received approval to begin a Phase IIb study with KB2115 in dyslipidemia patients receiving concomitant statin treatment.

The four-arm, placebo-controlled, parallel-group, double-blind, randomized, 12-week study will follow 172 patients who will receive 25-, 50- or 100-microgram doses of the candidate or placebo on top of statin treatment.

The results from the study are expected in the third quarter of 2008, Karo said.